NLS Pharmaceutics Management
Management criteria checks 4/4
NLS Pharmaceutics' CEO is Alex Zwyer, appointed in Aug 2015, has a tenure of 9.75 years. total yearly compensation is $610.00K, comprised of 90.2% salary and 9.8% bonuses, including company stock and options. directly owns 2.46% of the company’s shares, worth $68.32K. The average tenure of the management team and the board of directors is 4.3 years and 3.9 years respectively.
Key information
Alex Zwyer
Chief executive officer
US$610.0k
Total compensation
| CEO salary percentage | 90.16% |
| CEO tenure | 9.8yrs |
| CEO ownership | 2.5% |
| Management average tenure | 4.3yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
NLS Pharmaceutics gets delisting determination letter from Nasdaq
Oct 05NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate
Sep 27NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders
Jul 28Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation
Mar 04
Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$610k | US$550k | US$95k |
| Sep 30 2024 | n/a | n/a | -US$3m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | US$917k | US$863k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$15m |
| Mar 31 2023 | n/a | n/a | -US$16m |
| Dec 31 2022 | US$1m | US$977k | -US$16m |
| Sep 30 2022 | n/a | n/a | -US$16m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$1m | US$1m | -US$12m |
Compensation vs Market: Alex's total compensation ($USD610.00K) is about average for companies of similar size in the US market ($USD647.92K).
Compensation vs Earnings: Alex's compensation has been consistent with company performance over the past year.
CEO
Alex Zwyer (55 yo)
Mr. Alexander Zwyer, also known as Alex, M.B.A., Co-Founded NLS Pharmaceutics AG (formerly known as NLS Pharma AG) in 2015 until 2021 and serves as its Chief Executive Officer and Director since August 201...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$610.00k | 2.46% $ 68.3k | |
| Co-Founder & Chief Scientific Officer | 4.3yrs | US$108.00k | 1.7% $ 47.2k | |
| Chief Financial Officer | less than a year | US$54.00k | no data |
Experienced Management: NLSP's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$610.00k | 2.46% $ 68.3k | |
| Independent Chairman of the Board | 9.8yrs | US$22.00k | 19.02% $ 527.5k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 3.9yrs | US$14.00k | 0.41% $ 11.5k | |
| Independent Director | 1.3yrs | US$12.00k | no data |
Experienced Board: NLSP's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 11:42 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NLS Pharmaceutics AG is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| I-Eh Jen | Laidlaw & Company (UK) Ltd |